Join vTv Therapeutics for a virtual KOL event featuring leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego) and Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine) who will join company management to discuss:

• Challenges in the type 1 diabetes (T1D) treatment landscape
• Risks of hypoglycemia and the experience of living with T1D
• Cadisegliatin, vTv’s novel, potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of T1D
• An overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D

A live question and answer session will follow the formal presentations.